Skip to main content

Free Content Invasive Fungal Infections in Low-Risk Liver Transplant Recipients: A Multi-Center Prospective Observational Study

Download Article:

You have access to the full text article on a website external to Ingenta Connect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Prevention of invasive fungal infections (IFIs) in orthotopic liver transplant (OLT) recipients utilizing postoperative systemic antifungal prophylaxis, typically with fluconazole, is justified among those at high risk for IFI. Use of postoperative antifungal prophylaxis for low-risk OLT recipients is widely practiced but not universally accepted nor supported by data. We conducted a prospective observational study among 200 OLT recipients who were at low risk for IFI and did not receive postoperative antifungal prophylaxis. Patients were considered low risk if they had ≤1 of the following conditions: choledochojejunostomy anastomosis; retransplantation; intra-operative administration of ≥units of 40 blood products or return to the operating room for intra-abdominal bleeding; return to the operating room for anastomotic leak or vascular insufficiency; preoperative serum creatinine of ≥2 mg/dL; and perioperative Candida colonization. Patients were followed 100 d post-transplantation for evidence of IFI. Of 193 eligible patients, 7 (4%) developed an IFI. Three (2%) IFIs were due to Candida spp. and potentially preventable by standard fluconazole prophylaxis. Three patients developed invasive aspergillosis; one developed late onset disseminated cryptococcosis. Liver transplant recipients at low risk for IFI can be identified utilizing pre-determined criteria, and post-transplantation antifungal prophylaxis can be routinely withheld in these patients.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Antifungal; fungal infections; invasive candidiasis; liver transplant recipients; prophylaxis

Document Type: Research Article

Affiliations: 1: University of Wisconsin Health Sciences Center, Madison, WI 2: University of Pennsylvania Medical Center, Philadelphia, PA 3: New England – Tufts Medical Center, Boston, MA 4: University of Oregon Health Sciences Center, Portland, OR 5: University of Michigan Medical Center, Ann Arbor, MI 6: Rho Incorporated, Chapel Hill, NC 7: University of Alabama at Birmingham Medical Center 8: Beth Israel-Deaconess Medical Center, Boston, MA

Publication date: 01 February 2006

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more